dc.contributor.author |
Visentin, Andrea |
dc.contributor.author |
Espinet Solà, Blanca |
dc.contributor.author |
Gimeno Vázquez, Eva |
dc.contributor.author |
Ghia, Paolo |
dc.date.accessioned |
2024-09-27T06:20:53Z |
dc.date.available |
2024-09-27T06:20:53Z |
dc.date.issued |
2023 |
dc.identifier.citation |
Visentin A, Chatzikonstantinou T, Scarfò L, Kapetanakis A, Demosthenous C, Karakatsoulis G, et al. The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL. Am J Hematol. 2023 Dec;98(12):1856-68. DOI: 10.1002/ajh.27093 |
dc.identifier.issn |
0361-8609 |
dc.identifier.uri |
http://hdl.handle.net/10230/61253 |
dc.description.abstract |
In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, p = .0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations. |
dc.format.mimetype |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
Wiley |
dc.relation.ispartof |
Am J Hematol. 2023 Dec;98(12):1856-68 |
dc.rights |
© 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
dc.rights.uri |
http://creativecommons.org/licenses/by-nc/4.0/ |
dc.subject.other |
COVID-19 (Malaltia) |
dc.subject.other |
Leucèmia limfocítica crònica |
dc.title |
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL |
dc.type |
info:eu-repo/semantics/article |
dc.identifier.doi |
http://dx.doi.org/10.1002/ajh.27093 |
dc.rights.accessRights |
info:eu-repo/semantics/openAccess |
dc.type.version |
info:eu-repo/semantics/publishedVersion |